Company: Forozan OncoGen Consulting
Job title: President & Founder
Farahnaz is a Clinical PhD, an experienced Senior Leader w/ more than 22 years of experience (global including China & Australia) in pharma, IVD/medical device, clinical diagnostics, biotech, CRO/Central lab, academia, & hospital with specialized expertise in Strategy & Intelligence, complex & comprehensive translational build ups, translational & precision medicine, preclinical & clinical pipeline delivery from discovery through launch particularly in Oncology & Immuno-Oncology (& multiple sclerosis), biomarker identification, assay development, regulatory, quality, companion diagnostics, & driving therapeutics into diagnostics.
Proven track record in drug development & direct contributor to health authority interactions to ensure successful product launch based on commercialization plan, having contributed to the development, approval, &/or post marketing support of more than 15 marketed products & more than 30 global programs in various stages of clinical development.
Demonstrated experience, as member of the Leadership Search & Evaluation, Mergers & Acquisitions, and Diligent team of technical & strategy advisors, in various industries, in evaluation of assets, technologies, therapies, & startups, developing strategy for successful execution & launch of products, phase I-III trials, & launch of partnerships, including ones to co-develop & launch diagnostics w/ therapeutic drugs.
Farahnaz has also served as a global consultant (more than 17 years) conducting competitive intelligence, market analysis & trending, assessing new and innovative technologies/therapeutics/new platforms, providing expertise in assay development and automation, build up of new labs, working with major consulting/venture capital/investment, & law firms, start ups & incubators, accelerator programs, biotech, & pharma.
Farahnaz who until a few weeks ago was serving as Executive Director, Head of translational development at the Tumor Microenvironment Modulation, Thematic Research Center at BMS and was leading a new division she created, responsible for delivering on Discovery assets as well as launch and implementation of phase I and II oncology and IO trials, is now formally dedicating her time to consulting in advisory, SME, and SAB roles.